The biologics market is growing rapidly and during the next 5 years several biologics that have sales of more than $1 billion annually are scheduled to come off patent, providing the opportunity and incentive for biosimilar entry.
The development and manufacture of biosimilars are more complex compared to generics. the manufacturing complexity in each step involves a high degree of variability and hundreds of controlling input parameters, for safety and efficacy. Hence robust manufacturing, supply chain management and experience of the pharmaceutical manufacturer play a critical role.
Xeina Drugs offers high quality biosimilars with clinically proven biosimilarity, human clinical trial testing and comparative clinical trials for licensing to well established pharmaceuticals companies with the wherewithal to register and successfully market products of such high specialization.
Why license Biosimilars from Xeina Drugs
- Novel drugs portfolio, first entry biosimilars
- European Drug Substance and selected Drug products
- Human clinical trials, comparative trials and biosimilarity
- Open for FDF supply, API supply and full process technology transfer